Chronic Constipation Market

• The Chronic Constipation Market Size is anticipated to change, attributing to some major factors, like the increasing aging population, sedentary lifestyle, reduced intake of dietary fibers, and the widespread use of anti-inflammatory agents.
• Additionally, the easy accessibility of over-the-counter drugs for chronic constipation is anticipated to expand the market. The growing acceptance of unhealthy lifestyles also drives the growth of the chronic constipation treatment market.
• In the coming years, various key Chronic Constipation Companies such as Anji Pharma, Yuhan, RaQualia Pharma, Renexxion Ireland, and others with their assets in the early to mid-stages of development are expected to enter the therapy market stimulating growth in the Chronic Constipation treatment. With the anticipated approvals of all these projected therapies during the forecast period, the overall Chronic Constipation Therapeutics Market is expected to experience a substantial increase in the Compound Annual Growth Rate (CAGR).

Request for unlocking the Sample Page of the "Chronic Constipation Treatment Market'

DelveInsight’s report titled “Chronic Constipation Market Insights, Epidemiology, and Market Forecast – 2034” comprehensively analyzes Chronic constipation. The report includes a detailed examination of the historical and projected epidemiology data, including Total Prevalent Cases, Diagnosed Prevalent Cases, Gender-specific Diagnosed Prevalent Cases, and Age-specific Diagnosed Prevalent cases of Chronic Constipation. The market report on Chronic constipation provides comprehensive insights into different aspects concerning the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and future developments across the seven major markets, namely the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

The Chronic Constipation Therapeutics Market Report examines current treatment practices and unmet medical needs in Chronic Constipation. It assesses the market potential and identifies business opportunities for improved therapies or interventions. This helps stakeholders make informed decisions for product development and market strategies.

Chronic Constipation Treatment Market

Chronic constipation is a common digestive disorder characterized by infrequent bowel movements and difficulty passing stool. It is a chronic condition that persists over an extended period, typically several weeks or more. While occasional constipation is normal and usually resolves independently, chronic constipation is more persistent and bothersome. Symptoms include infrequent bowel movements (less than three per week) and difficulty passing stool, often resulting in straining and hard, lumpy stools.

The most common triggers of constipation include slow movement of stool through the colon, difficulty eating a balanced diet, with a lack of fiber from fruit and vegetables, inadequate fluid intake leading to dehydration, lack of exercise leading to slowed digestion, irritable bowel syndrome, side effects of medications, mental health problems, including stress, anxiety, depression, eating disorders.

Chronic Constipation Diagnosis

Diagnosing chronic constipation is accomplished through a comprehensive approach that involves reviewing the patient’s medical history, conducting a physical examination, and utilizing diagnostic tests such as blood tests to exclude underlying conditions and imaging studies like X-rays or colonoscopy to assess the colon’s structure and rule out any abnormalities. However, this process can be challenging due to the patient’s underreporting symptoms; symptom overlaps with other gastrointestinal disorders, the absence of specific diagnostic tests, and the lack of standardized criteria, necessitating thorough evaluation by healthcare professionals.

Chronic Constipation Treatment Landscape

The management of chronic constipation involves a stepwise approach. Initially, algorithms and guidelines exclude secondary pathologies and causes. If available, lifestyle modifications and dietary adjustments are then adopted, along with behavioral measures. If these measures prove ineffective, laxatives such as bulk-forming, osmotic, and stimulant types are considered. When symptoms persist, a prokinetic agent like prucalopride may be prescribed. In cases with disordered defecation, biofeedback is recommended as a treatment option. After exhausting all other treatment options, surgery should only be considered a last resort.

Chronic Constipation Epidemiology

The epidemiology section on the Chronic constipation market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of chronic constipation. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

• According to Yamamoto et al. (2022), in an online survey conducted in the US, the prevalence of chronic constipation was reported to be 5.5% according to the Rome III criteria, and it was found to be 2.1% based on medical consultations in Japan.
• According to the Comprehensive Survey of Living Conditions in Japan (2017), constipation is more prevalent in women than men. However, the number of men with constipation increases at the age of > 70 years, with approximately equal occurrence at the age of ≥80 years.
• As per Roque and Bouras (2015), a population-based study reported that the cumulative incidence of chronic constipation (CC) is higher in elders (~20%) compared to a younger population. Severe constipation is more common in older women, with rates of constipation two to three times higher than that of their male counterparts.
• Enck et al. (2015), reported variable prevalence rates between 2.4% and 35% for chronic constipation across different countries worldwide, with a low 5% for Germany.
• According to a review article by Shin (2021), chronic constipation accounts for approximately 1 million hospital visits annually in the US. The article also predicted that the prevalence of chronic constipation is expected to increase in the future.
• The Chronic Constipation Prevalence is projected to rise as the population ages, given that older individuals have higher rates of this condition than younger age groups. As the global population ages, there will likely be an increased burden of chronic constipation, highlighting the need for effective management and interventions to address this growing health concern.

Unlock comprehensive insights! Click Here to Purchase the Full Epidemiology Report @ Chronic Constipation Prevalence

Chronic Constipation Recent Developments

• In January 2025, NeurAxis Inc. received FDA 510(k) clearance for its Rectal Expulsion Device (RED), designed to test and evaluate patients with chronic constipation due to pelvic floor dyssynergia who may not benefit from increased laxative use.
• In December 2024, NeurAxis, Inc. announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for its Rectal Expulsion Device (RED), enabling the company to commercially market the device for testing and evaluating patients with chronic constipation due to pelvic floor dyssynergia who are unlikely to improve with increased laxative use.

Chronic Constipation Market Outlook

Various treatment options are available for chronic constipation, including over-the-counter laxatives, prescription medications, dietary modifications, and lifestyle changes. The demand for these treatments is expected to remain strong as the burden of chronic constipation continues to rise globally. Fiber supplements have been demonstrated to improve functional constipation. As per current literature evidence, osmotic and stimulant laxatives should be used as the first treatment strategies in patients with chronic constipation. Furthermore, there is good evidence of efficacy for using PEG with substantial osmotic activity. PEG 3350 is effective for the short-term treatment of constipation. It has been approved as an over-the-counter treatment for occasional constipation.

Linaclotide, marketed as LINZESS, is an anti-constipation agent that exerts its effects through the Heat Stable Enterotoxin Receptor (Guanylyl Cyclase C or Intestinal Guanylate Cyclase or GUCY2C or EC 4.6.1.2) Agonist mechanism of action. It received its first approval in 2012 and is currently available globally, including the US, the UK, France, Germany, China, and Japan, through its distribution by Allergan Sales LLC. Lubiprostone is another addition to the treatment armamentarium for symptoms associated with chronic constipation and IBS-C. Based on clinical studies demonstrating the safety and efficacy of lubiprostone for treating chronic constipation, the FDA approved lubiprostone in January 2006 for treating chronic constipation in adults.

Resolax (Prucalopride), generic Montegrity, is a prescription medicine used to treat chronic idiopathic (the cause of the constipation is unknown) constipation (CIC) in whom laxative medications fail to provide adequate relief. Surgical interventions may be used if medical treatment fails in constipated patients, and mechanical emptying of the colon may be recommended in patients with slow bowel movements using an enema program.

Moreover, there has been a focus on developing novel therapies that address the unmet medical needs of chronic constipation. Pharmaceutical companies are investing in research and development to create more effective and well-tolerated treatments for patients, potentially expanding the market further. The primary goal of research to generate new agents to treat chronic constipation is to normalize gut transit and bowel function by accelerating colonic transit, stimulating gut motility, facilitating defecation, and/or promoting secretion by the intestinal mucosa.

"According to DelveInsight, the Chronic constipation Treatment Market in the 7MM is expected to change significantly during the study period 2020–2034"

Marketed Chronic Constipation Drugs

• LINZESS (linaclotide): ABBVIE

LINZESS (linaclotide) is a guanylate cyclase-C agonist that is indicated for the treatment of several gastrointestinal conditions. It is approved for use in adults with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). LINZESS is also indicated for treating functional constipation (FC) in pediatric patients aged 6–17 years. This medication offers a treatment option for individuals of different ages suffering from these specific gastrointestinal disorders. It is prescribed for treating irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in cases where dietary fiber, laxatives, and stool softeners have not provided satisfactory results.

• GOOFICE: Eisai Co., Ltd.

EA Pharma has obtained the rights for GOOFICE Tablet from Albireo AB. This constipation treatment is taken orally once a day and features a unique mechanism of action. GOOFICE Tablet inhibits the bile acid transporter responsible for regulating bile acid reabsorption, increasing bile acid flow to the colon, and promoting natural defecation. Through this novel mechanism, EA Pharma, Eisai, and Mochida aim to expand the range of treatment choices available to patients with chronic constipation to enhance their quality of life. The drug is approved in Japan.

Note: Detailed marketed therapies assessment will be provided in the final report…

Emerging Chronic Constipation Drugs

The Chronic constipation market dynamics are anticipated to undergo a striking transformation primarily driven by the global increase in healthcare expenditure. Chronic constipation Market players such as Anji Pharma, RaQualia Pharma, Renexxion Ireland, and others are actively involved in developing Chronic constipation treatments.

• ANJ908 (Pradigastat):  Anji Pharma

ANJ908, also known as pradigastat, is a novel investigational oral drug developed by Anji Pharmaceuticals. ANJ908 is an inhibitor of diacylglycerol acyltransferase 1 (DGAT1), an enzyme responsible for catalyzing the re-assembly of meal triglycerides in the intestine. The company has conducted a Phase II clinical Proof of Concept (PoC) trial of ANJ908 (pradigastat) in patients with chronic idiopathic constipation. The trial included participants from the US and China. With its promising results, ANJ908 (Pradigastat) holds significant potential to enhance chronic constipation’s management greatly.

• YH12852: Yuhan

YH12852, developed by Yuhan, is a potent and selective receptor agonist of 5-hydroxytryptamine (5-HT). It has shown promising results in increasing gastrointestinal motility in both healthy volunteers and patients with functional constipation. The drug is undergoing Phase II clinical trials to evaluate its safety and efficacy further.

Note: Detailed emerging therapies assessment will be provided in the final report...

Chronic Constipation Market Segmentation

DelveInsight’s ‘Chronic Constipation Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a detailed outlook of the current and future Chronic constipation market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Chronic Constipation Market Size by Countries

The total Chronic constipation market size is analyzed for individual countries (the United States Market, EU4 [Germany, France, Italy, and Spain] and the UK market, and Japan). The United States accounted for a larger portion of the 7MM market for Chronic constipation in 2022 due to the high prevalence of the condition and the higher cost of treatments. This dominance is predicted to continue with the potential early entry of new products.

Chronic Constipation Market Size by Therapies

Chronic constipation market size by therapies is categorized into current and emerging markets for the study period 2020–2034. One of the emerging drugs anticipated to launch during the forecast period is ANJ908/Pradigastat, under the developmental pipeline of Anji Pharma.

Note: Detailed market segment assessment will be provided in the final report…

Chronic constipation Drugs Uptake

This section focuses on the sales uptake of potential Chronic constipation drugs that have recently been launched or are anticipated to be launched in the Chronic constipation market between 2020 and 2034. It estimates the market penetration of Chronic constipation drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the Chronic constipation market.

The emerging Chronic constipation therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet needs they will fulfill in the Chronic constipation market.

Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on Chronic constipation…

Chronic Constipation Market Access and Reimbursement

DelveInsight’s ‘Chronic Constipation Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a descriptive overview of chronic constipation’s market access and reimbursement scenario. This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current Chronic constipation market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the Chronic constipation domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or Chronic constipation market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Chronic constipation unmet needs.

Chronic constipation: KOL Insights

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as the Tufts University School of Medicine in Boston, the Division of Gastroenterology and Hepatology, Indiana University School of Medicine in the US, Department of Internal Medicine, Park-Klinik Weissensee in Germany, and others.

“Laxative use is common for chronic constipation among the European countries.”

Note: Detailed assessment of KOL Views will be provided in the full report on Chronic constipation...

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the Chronic Constipation Market, utilizing various Competitive Intelligence tools such as SWOT analysis and market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Chronic Constipation Pipeline Development Activities

The Chronic Constipation therapeutics market report offers an analysis of the Chronic Constipation Clinical Trials within Phase II and III stages and examines the companies involved in developing targeted therapeutics for chronic constipation. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The Chronic Constipation therapeutics market report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging Chronic constipation therapies.

Chronic Constipation Therapeutics Market Report Insights

• Patient-based Chronic Constipation Market Forecasting
• Chronic constipation Therapeutic Approaches
• Chronic Constipation Pipeline Drugs Analysis
• Chronic Constipation Market Size and Trends
• Chronic Constipation Market Opportunities
• Impact of Upcoming Chronic constipation Therapies

Chronic Constipation Therapeutics Market Report Key Strengths

• 10 Years Chronic Constipation Market Forecast
• The 7MM Coverage
• Chronic Constipation Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Chronic Constipation Drugs Market
• Chronic constipation Drugs Uptake

Chronic Constipation Therapeutics Market Report Assessment

• Current Chronic Constipation Treatment Market Practices
• Chronic constipation Unmet Needs
• Chronic Constipation Pipeline Drugs Profiles
• Chronic Constipation Drugs Market Attractiveness
• Chronic constipation Market Drivers
• Chronic constipation Market Barriers

Key Questions Answered

• What are the key findings of the Chronic Constipation epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020-2034)?
• What are the currently available Chronic Constipation treatment?
• What is the disease risk, burden, and Chronic Constipation Unmet Needs?
• At what CAGR is the Chronic constipation market, and its epidemiology is expected to grow in the 7MM forecast period (2023–2034)?
• How would the unmet needs impact the Chronic constipation market dynamics and subsequently influence the analysis of related trends?
• What would be the forecasted patient pool for Chronic constipation in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2023-2034)?
• How many companies are currently developing therapies for the Chronic constipation treatment?

Stay Updated with us for Recent Articles

• Chronic Constipation Market: Infographics
• Latest DelveInsight Blogs